Are Your Patients with COVID-19 Eligible for Monoclonal Antibody Treatment?

March 2, 2021

Patients who test positive for COVID-19 may qualify to receive monoclonal antibody treatment (casirivimab and imdevimab).

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for these medications last November for mild or moderate cases of COVID-19 in adults and children who are at high risk with at least one health condition. Monoclonal antibodies are not to be used for patients already in the hospital or patients using oxygen.

In a clinical trial of patients with COVID-19, monoclonal antibody treatment reduced hospitalization or emergency room visits in high risk patients. The safety and effectiveness of this treatment for COVID-19 continues to be evaluated.

The U.S. Department of Health and Human Services offers a resource to help patients find locations for monoclonal antibody treatment: Therapeutics Distribution Locations.
Share this article:

Cookie Consent

Cookies are required for some functionality on our site. View our privacy policy for more information.